- Home
- MEDP vs BMRN Comparison
MEDP vs BMRN Comparison
Compare MEDP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- BMRN
- Stock Information
- Founded
- MEDP 1992
- BMRN 1996
- Country
- MEDP United States
- BMRN United States
- Employees
- MEDP N/A
- BMRN N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MEDP Health Care
- BMRN Health Care
- Exchange
- MEDP Nasdaq
- BMRN Nasdaq
- Market Cap
- MEDP 13.4B
- BMRN 10.5B
- IPO Year
- MEDP 2016
- BMRN 1999
- Fundamental
- Price
- MEDP $585.14
- BMRN $54.46
- Analyst Decision
- MEDP Hold
- BMRN Buy
- Analyst Count
- MEDP 12
- BMRN 19
- Target Price
- MEDP $465.18
- BMRN $90.26
- AVG Volume (30 Days)
- MEDP 324.1K
- BMRN 2.8M
- Earning Date
- MEDP 10-22-2025
- BMRN 10-27-2025
- Dividend Yield
- MEDP N/A
- BMRN N/A
- EPS Growth
- MEDP 25.36
- BMRN 59.53
- EPS
- MEDP 14.32
- BMRN 2.68
- Revenue
- MEDP $2,358,373,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- MEDP $21.48
- BMRN $13.32
- Revenue Next Year
- MEDP $11.90
- BMRN $7.51
- P/E Ratio
- MEDP $40.91
- BMRN $20.33
- Revenue Growth
- MEDP 13.88
- BMRN 12.39
- 52 Week Low
- MEDP $250.05
- BMRN $50.76
- 52 Week High
- MEDP $625.00
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- MEDP 57.97
- BMRN 53.97
- Support Level
- MEDP $573.07
- BMRN $53.67
- Resistance Level
- MEDP $609.13
- BMRN $55.34
- Average True Range (ATR)
- MEDP 16.64
- BMRN 1.59
- MACD
- MEDP -3.57
- BMRN 0.31
- Stochastic Oscillator
- MEDP 38.72
- BMRN 81.22
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.